[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337606-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337606-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","performance-of-oc-auto-micro-80-fecal-immunochemical-test-in-an-integrated-academic-community-health-system","Performance of OC-Auto Micro 80 Fecal Immunochemical Test in an Integrated Academic-Community Health System","","Retrospective cohort analysis evaluates OC-Auto Micro 80 fecal immunochemical test (FIT) performance for colorectal cancer screening in a heterogeneous, average-risk population served by an integrated academic-community health system. Study uses electronic health records to quantify FIT positivity, colonoscopy completion, and pathology outcomes, including positivity by sex and differences between safety-net and non–safety-net settings. Among 39,984 FITs completed by 26,384 patients, positivity was 6.0%, with CRC positive predictive value of 3.0% after colonoscopy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/performance-of-oc-auto-micro-80-fecal-immunochemical-test-in-an-integrated-academic-community-health-system/337606/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/performance-of-oc-auto-micro-80-fecal-immunochemical-test-in-an-integrated-academic-community-health-system/337606.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study?","Question",{"text":63,"@type":64},"To determine the performance of the OC-Auto Micro 80 fecal immunochemical test (FIT) in an average-risk population receiving care in an integrated academic-community health system.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What outcomes were measured?",{"text":68,"@type":64},"Primary outcomes were FIT positivity rate and neoplasms detected at colonoscopy. Secondary outcomes included FIT positivity by sex and comparisons between safety-net and non–safety-net clinical settings.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings for FIT positivity and CRC detection?",{"text":72,"@type":64},"Among 39,984 completed FITs, 6.0% were positive, and for those completing colonoscopy after an abnormal FIT, the positive predictive value for CRC was 3.0%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337606,1790127974,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Performance of OC-Auto Micro 80 Fecal Immunochemical Test in an Integrated Academic-Community Health System  \nLindsey Durowoju, MD,* Patrick C. Mathias, MD, PhD,*† Ari Bell-Brown, MPH,‡ Nathan Breit, BSc,* Hsuan-Chieh Liao, PhD,* Wynn Burke, MS,§ and Rachel B. Issaka, MD, MAS‡§∥  \nGoals: We aimed to determine the performance of the OC-Auto Micro 80 fecal immunochemical test (FIT) in an average-risk population receiving care in an integrated, academic-community health system.  \nBackground: The FIT is the most used colorectal cancer (CRC) screening test worldwide. However, many Food and Drug Administration–cleared FIT products have not been evaluated in clinical settings.  \nStudy: We performed a retrospective cohort study of patients (50 to 75 y old) in the University of Washington Medicine health care system who were screened for CRC by OC-Auto Micro 80 FIT between March 2016 and September 2021 . We used electronic health records to extract patient-level and clinic-level factors, FIT use, colonoscopy, and pathology ﬁndings. The primary outcomes were the FIT positivity rate and neoplasms detected at colonoscopy. Secondary outcomes were FIT positivity by sex and safety-net versus non–safety-net clinical settings.  \nResults: We identiﬁed 39,984 FITs completed by 26,384 patients; 2411 (6 .0%) had a positive FIT result ( > 100 ng/mL of hemoglobin in buffer), and 1246 (51 .7%) completed a follow-up colonoscopy. The FIT positive rate was 7 .0% in men and 5 .2% in women (P \u003C0.01) . Among those who completed a colonoscopy after an abnormal FIT result, the positive predictive value for CRC, advanced adenoma, and advanced neoplasia was 3.0%, 20.9%, and 23.9%, respectively.  \nConclusions: In a retrospective analysis of a large heterogeneous population, the OC-Auto Micro 80 FIT for CRC screening demonstrated a positivity rate of 6.0% and a positive predictive value for CRC of 3 .0% .  \nKey Words: colorectal cancer, screening, fecal immunochemical test, colonoscopy  \n(J Clin Gastroenterol 2024;58:602–606)  \nReceived for publication May 4, 2023; accepted August 17, 2023 .  \nFrom the Departments of *Laboratory Medicine and Pathology;†Biomedical Informatics and Medical Education, University of Washington School of Medicine; §Division of Gastroenterology, University of Washington School of Medicine; ‡Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Center; and ∥Public Health Sciences & Clinical Research Divisions,  \nFred Hutchinson Cancer Center, Seattle, WA. The authors declare that they have nothing to disclose.  \nAddress correspondence to: Rachel B. Issaka, MD, MAS, 1100 Fairview Ave. N, M/S: M3-B232, Seattle, WA 98109 (e-mail: [rissaka@fredhutch.org](rissaka@fredhutch.org)).  \nCopyright © 2023 The Author(s) . Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nDOI: 10.1097/MCG.0000000000001928  \nColorectal cancer (CRC) is the second leading cause of  \ncancer-related deaths in men and women in the United States.1 CRC is the only cancer for which screening has been proven to reduce mortality in both average-risk men and women.2 The US Preventive Services Task Force recommends routine CRC screening for adults between the ages of 45 and 75 .3 As a result of increased screening, among other factors, CRC mortality has declined by over 50% in the past 3 decades.4  \nThe fecal immunochemical test (FIT) is one method of stool-based screening and the most used CRC screening test worldwide.5 OC-Auto Micro 80 is a quantitative FIT assay that measures hemoglobin in a patient’s stool sample by using antihuman hemoglobin antibodies that bind to hemoglobin. Compared with the original stool-based CRC screening method","cbCais3zT7sVdmqE","https://ap.wps.com/l/cbCais3zT7sVdmqE","pdf",119265,"English","# Goals\n# Background\n# Study Design and Population\n# Results\n# Conclusions\n# Key Words","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To determine the performance of the OC-Auto Micro 80 fecal immunochemical test (FIT) in an average-risk population receiving care in an integrated academic-community health system.\"},{\"question\":\"What outcomes were measured?\",\"answer\":\"Primary outcomes were FIT positivity rate and neoplasms detected at colonoscopy. Secondary outcomes included FIT positivity by sex and comparisons between safety-net and non–safety-net clinical settings.\"},{\"question\":\"What were the key findings for FIT positivity and CRC detection?\",\"answer\":\"Among 39,984 completed FITs, 6.0% were positive, and for those completing colonoscopy after an abnormal FIT, the positive predictive value for CRC was 3.0%.\"}]","Performance of OC-Auto Micro 80 Fecal Immunochemical Test in an Integrated Academic-Community Health System | PDF",1790019760,13,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36dff2ffbee1e1639b915da75227afaf.webp",983,1363,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eacfe93dedb633580f02d5fcdc0aff64.webp",982,1362,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d941b30a60ab065c70c611b370949828.webp",981,1361,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c49bea991ef2ec211ce6139dc1cf5086.webp",980,1359]